An Endoplasmic Reticulum Stress‐Specific Nanoinducer Selectively Evokes Type‐II Immunogenic Cell Death for Pyroptotic Cancer Immunotherapy
Advanced Materials · 2025-08 · 37 (32)
DOI: 10.1002/adma.202501953 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, online erschienen am 28.05.2025. Verfasst von Yimeng Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China. Hauptthemen laut MEDLINE: Endoplasmic Reticulum Stress, Immunogenic Cell Death, Immunotherapy, Pyroptosis. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 62 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Specific induction of endoplasmic reticulum (ER) stress‐initiated type‐II immunogenic cell death (ICD) shows great potential in boosting tumor immunogenicity and anti‐tumor immunotherapy. However, it remains challenging to selectively provoke type‐II ICD, due to the lack of highly efficient ER targeting strategy. Here, a pH/Cathepsin‐Activatable Nanoplatform (PCAN) is reported to specifically photo‐induce ER stress (PCAN ER ) and type‐II ICD for cancer immunotherapy. PCAN ER integrates the long‐circulating properties of nanomedicines with pH/cathepsin B dual‐gated design, exhibiting excellent ER targeting with a colocalization efficacy of 83% in cancer tissues. Through directly intensifying glucose‐regulated protein 78 and calreticulin exposure, PCAN ER augments type‐II ICD and pyroptotic cancer cell death with high immune priming to cascade‐amplify the cancer‐immunity cycle, while the mild type‐I ICD induced by lysosome stress (PCAN Ly ) exhibits negligible antitumor efficacy. By leveraging the spatiotemporal subcellular organelle targeting of PCAN technology, this study achieves precise tuning of the type of ICD and cellular pyroptosis‐based cancer therapy. This study offers new insights into the design of organelle level‐targeted nanomedicines, paving the way for dissecting and modulating the cell death mechanism to boost cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmacy, Shenyang Pharmaceutical University, Shenyang, Liaoning, 110016, China.
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
- Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.
- Department of Central Laboratory, Peking University First Hospital, Beijing, 100034, China.
- Chemical Biology Center, Peking University, Beijing, China.
- Ningbo Institute of Marine Medicine, Peking University, China.
ORCID-Profile: Yimeng Zhang, Yiguang Wang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Y., Yan, Y., Liu, J., Xia, H., Zhou, J., Cui, Y., Huang, X., Chang, J., Zhang, W., Chen, W., Zhang, Q., Wang, S., Wang, Y., & Chen, B. (2025). An Endoplasmic Reticulum Stress‐Specific Nanoinducer Selectively Evokes Type‐II Immunogenic Cell Death for Pyroptotic Cancer Immunotherapy. Advanced Materials, 37(32). https://doi.org/10.1002/adma.202501953
Vancouver
Zhang Y, Yan Y, Liu J, Xia H, Zhou J, Cui Y, et al. An Endoplasmic Reticulum Stress‐Specific Nanoinducer Selectively Evokes Type‐II Immunogenic Cell Death for Pyroptotic Cancer Immunotherapy. Advanced Materials. 2025;37(32). doi:10.1002/adma.202501953
BibTeX
@article{Zhang2025,
author = {Zhang, Yimeng and Yan, Yue and Liu, Jianxiong and Xia, Heming and Zhou, Jiayi and Cui, Yi and Huang, Xinyu and Chang, Jian and Zhang, Weiwei and Chen, Wei and Zhang, Qiang and Wang, Siling and Wang, Yiguang and Chen, Binlong},
title = {An Endoplasmic Reticulum Stress‐Specific Nanoinducer Selectively Evokes Type‐II Immunogenic Cell Death for Pyroptotic Cancer Immunotherapy},
journal = {Advanced Materials},
year = {2025},
volume = {37},
number = {32},
doi = {10.1002/adma.202501953}
}
EUVIMED